Saturday 17 October 2026 Export INGN’s income statement to Excel — free account

Inogen, Inc

Inogen, Inc’s revenue for fiscal 2025 (year ended December 2025) was $348.7 million, up 3.86% from fiscal 2024. In the quarter to June 2026, revenue grew 3.04%, EPS grew 6.67% and free cash flow fell 51.2%, each against the same quarter a year earlier.

6.25 0.05 −0.79%

Follow INGN

Alert me

Market cap: $167.1M
P/E: 0.0×
Fwd P/E: −8.2×
Dividend yield: —
F-score: 5/9
Altman Z: 1.56
Beneish M: −2.32
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	1	—	1	—	—	—

Insider Ownership 5.49%

Capital & Financial Ratios $m

Market Cap 167.06

Revenue 354.30

Net Income (24.59)

Free Cash Flow (7.86)

Net Debt (106.84)

Current Ratio 2.74

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (8.18)

P/S ratio 0.48

P/B ratio 0.97

Past 5Y EPS Growth —

This Y EPS Growth 11.17%

Next Y EPS Growth 37.58%

Next Y revenue growth 2.22%

Next 5Y EPS Growth 32.01%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 8.70%

10-year low 10-year high

P/B against its own 10 years 18.65%

10-year low 10-year high

EV/Sales against its own 10 years 12.18%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	128	117	121	107
Receivables	43	30	39	46
Inventory	22	25	26	29
Other	—	—	—	—
	207	185	198	194

	2023	2024	2025	Q'26
Payables	30	27	34	40
ST’ Debt	—	—	—	—
Other	20	23	10	10
	72	77	64	71

Compound Annual Growth %

	10y	5y	3y
Sales	8.17%	2.48%	(2.59%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	3.67%	(11.28%)	(13.54%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	85	95	—	—	—
’25	82	92	92	82	349
’24	78	89	89	80	336
’23	72	84	84	76	316
’22	80	103	105	88	377
’21	87	102	93	76	358
’20	88	72	74	74	308

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	3	—	—	—
’25	(17)	4	2	(1)	(11)
’24	(5)	7	7	(3)	6
’23	(6)	4	2	(3)	(3)
’22	(18)	6	(9)	(15)	(38)
’21	3	17	(3)	6	24
’20	1	14	7	16	37

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	1	—	—	—
’25	(17)	3	1	(2)	(14)
’24	(6)	5	5	(3)	0
’23	(7)	1	1	(5)	(9)
’22	(19)	5	(10)	(16)	(41)
’21	1	15	(4)	6	18
’20	(1)	12	6	15	32

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.30)	(0.14)	—	—	—
’25	(0.25)	(0.15)	(0.20)	(0.26)	(0.86)
’24	(0.62)	(0.24)	(0.25)	(0.41)	(1.52)
’23	(0.88)	(0.42)	(1.97)	(1.14)	(4.42)
’22	(0.62)	(0.15)	(0.42)	(2.47)	(3.67)
’21	(0.03)	0.22	0.53	(1.01)	(0.28)
’20	(0.07)	0.12	(0.08)	(0.23)	(0.27)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	28.81	62.69	110.51	41.19	26.57	29.28	19.08	4.13	5.08	5.70	Analyst estimates 2026–2028 Powerpack
	High	69.36	130.05	287.79	155.75	68.68	82.35	36.30	26.11	13.33	12.91
People
People	Employees	166	770	1,099	1,020	938	1,021	1,026	834	766	753
	Revenue/emp, $m	1.22	0.32	0.33	0.35	0.33	0.35	0.37	0.38	0.44	0.46
Income, $m
Income, $m	Revenue	203	249	358	362	308	358	377	316	336	349
	Gross margin, %	47.98	48.60	49.87	47.48	44.79	49.30	40.70	40.14	46.09	44.24
	EBT	23	30	40	24	(5)	9	(83)	(102)	(36)	(23)
	EBT margin, %	11.20	11.89	11.30	6.71	(1.71)	2.42	(22.07)	(32.42)	(10.87)	(6.71)
	Net income	21	21	52	21	(6)	(6)	(84)	(102)	(36)	(23)
	Depreciation	14	12	11	14	19	22	24	18	21	21
Per share, $
Per share, $	Revenue	10.11	12.06	16.84	16.59	14.03	15.92	16.51	13.62	14.19	13.11
	Earnings	1.02	1.02	2.44	0.96	(0.27)	(0.28)	(3.67)	(4.42)	(1.52)	(0.86)
	Cash flow	1.55	2.92	2.82	1.86	1.68	1.05	(1.64)	(0.14)	0.25	(0.42)
	Capex	(0.09)	(0.30)	(0.39)	(0.16)	(0.21)	(0.25)	(0.15)	(0.25)	(0.23)	(0.09)
	Free cash flow	1.46	2.62	2.43	1.70	1.47	0.80	(1.79)	(0.39)	0.02	(0.52)
	Book value	9.07	10.98	14.60	15.79	15.91	16.46	13.01	8.84	7.35	7.23
	Shares, m	20	21	21	22	22	22	23	23	24	27
Valuation, ×
Valuation, ×	P/E	64.56	117.99	50.89	71.18	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	6.49	9.88	7.37	4.12	3.18	2.14	1.20	0.42	0.65	0.51
	P/B	7.22	10.86	8.51	4.33	2.81	2.07	1.53	0.64	1.25	0.93
	EV/Sales	5.92	9.19	6.70	3.54	2.43	1.45	0.71	0.01	0.30	0.17
	EV/FCF	41.20	42.31	49.73	34.47	23.20	28.82	(6.53)	(0.35)	214.77	(3.27)
Cash, $m
Cash, $m	Operating cash flow	31	60	60	41	37	24	(38)	(3)	6	(11)
	Capex	(2)	(6)	(8)	(3)	(5)	(6)	(3)	(6)	(5)	(3)
	Free cash flow	29	54	52	37	32	18	(41)	(9)	0	(14)
Balance, $m
Balance, $m	Working capital	139	195	268	242	249	268	239	135	109	135
	Total debt	—	—	—	2	2	3	4	—	—	—
	Net debt	(114)	(174)	(240)	(209)	(231)	(246)	(187)	(128)	(117)	(121)
	Shareholders’ equity	182	227	310	345	350	370	297	205	174	192
Returns, %
Returns, %	ROA	10.93	8.59	15.93	5.09	(1.28)	(1.33)	(18.73)	(28.02)	(11.53)	(7.65)
	ROIC	20.95	32.48	33.80	9.13	(6.35)	4.63	(48.26)	(89.55)	(47.08)	(26.45)
	ROE	12.98	10.27	19.29	6.40	(1.68)	(1.76)	(25.10)	(40.80)	(18.95)	(12.43)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%	Compare
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)	Compare
RXST RxSight, Inc.	$194.2M	— (loss-making)	— (loss-making)	+0.31% (above 0%: growing)	n/m	−94.39% (below 0%: shrinking)	76.72%	(40.81%)	Compare
INGN Inogen, Inc	$167.1M	— (loss-making)	— (loss-making)	+3.04% (above 0%: growing)	n/m	−51.15% (below 0%: shrinking)	45.51%	(5.36%)
STIM Neuronetics, Inc.	$148.6M	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+62.06% (above 0%: growing)	51.06%	(3.61%)	Compare
QTRX Quanterix Corporation	$145.2M	— (loss-making)	— (loss-making)	+34.44% (above 0%: growing)	n/m	+18.92% (above 0%: growing)	38.52%	(150.22%)	Compare
MXCT MaxCyte, Inc.	$134.2M	— (loss-making)	— (loss-making)	−14.53% (below 0%: shrinking)	n/m	+54.74% (above 0%: growing)	76.96%	(140.72%)	Compare
OWLT Owlet, Inc.	$129.8M	— (loss-making)	— (loss-making)	+29.94% (above 0%: growing)	n/m	+55.74% (above 0%: growing)	64.44%	5.14%	Compare
Median of peers	$171.4M	—	—	+10.36%	—	+18.22%	76.84%	(63.42%)

All 149 Medical Devices stocks →

Inogen, Inc (INGN) key facts

Strength: Inogen, Inc’s revenue for fiscal 2025 (year ended December 2025) was $348.7 million, up 3.86% from fiscal 2024.
Inogen, Inc (INGN) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, INGN traded at $6.25, a market capitalization of $167.1 million.
Return on equity was −12.4% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.56 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.